Graves Ophthalmopathy Market Overview
The most common extrathyroidal symptom of Graves' illness is ophthalmopathy, sometimes called thyroid-associated ophthalmopathy and thyroid eye disease. This autoimmune condition causes the orbit to become inflamed as a result of the generation of autoantibodies. The thyroid and orbit both share a protein that the autoantibodies are thought to target.
Graves Ophthalmopathy Epidemiology Segmentation in the 7MM from 2019 to 2032
- Prevalent Cases
- Diagnosed Prevalent Cases
- Gender-specific Diagnosed Prevalent Cases
- Diagnosed Prevalent Cases by Chronicity
- Moderate-to-severe Drug-treated Cases of Acute Graves’ Ophthalmopathy
Graves Ophthalmopathy Epidemiology Insights (2022)
The Total Graves Ophthalmopathy prevalent cases in the 7MM were ~2.3 million cases in 2022
Graves Ophthalmopathy Market Insight (2022)
The Graves Ophthalmopathy Market size in the 7MM was valued ~USD 2 billion in 2022
Graves Ophthalmopathy Market Strengths
- Recent FDA approval of Horizon’s TEPEZZA
- Efforts to increase patient and clinician awareness
Graves Ophthalmopathy Market Opportunities
- Lack of availability of disease-modifying treatment
- Development of ocular drug discovery programs
Graves Ophthalmopathy Emerging Drugs and key companies
- Batoclimab (IMVT 1401): Immunovant Sciences
- COSENTYX (secukinumab): Novartis
- VRDN-001: Viridian Therapeutics
- Linsitinib: Sling Therapeutics
- Aflibercept: Regeneron Pharmaceuticals
- VB421: ValenzaBio, and others